Ginkgo Bioworks Holdings, Inc. DNA
Set alert
At close
Pre-market · Nov 2, 8:50 AM ET
- YTD
- +34.90%
- 1 year
- -6.66%
- Open
- 12.12
- Prev close
- 12.74
- Mkt cap
- 754.88M
- Vol
- 2.73M
- Avg vol
- 2.23M
- EPS
- -5.06
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.61
- High
- 12.61
- Forward P/E
- -5.17
- Beta
- 1.79
- Short ratio
- 6.35
- Inst. own
- 73.73%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 8.08
- 200-d avg
- 8.32
- 1y target
- 7.00
6M chart
Events in this range
- May 7, 2026Earnings: -1.39; estimate -1.21115; surprise -14.77%
- Aug 5, 2026Earnings: -0.75; estimate -0.895; surprise 16.2%
- Aug 7, 2026Downgrade: TD Cowen · Buy → Hold
- Sep 4, 2026Rating: BTIG · Sell → Sell
Signals (32)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 29, 2026 | 4 days ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| RSI: Overbought | Sep 24, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| RSI: Overbought | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 25, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 11, 2026 | 2 months ago |
| SMA: Bearish | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 17, 2026 | 3 months ago |
| SMA: Bearish | Jul 16, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 8, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 18, 2026 | 4 months ago |
| SMA: Bullish | Jun 17, 2026 | 4 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | Jun 10, 2026 | 4 months ago |
| SMA: Bearish | Jun 10, 2026 | 4 months ago |
| SMA: Bullish | Jun 9, 2026 | 4 months ago |
| SMA: Bearish | Jun 8, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 5, 2026 | 5 months ago |
| MACD: Buy Signal | May 28, 2026 | 5 months ago |
| SMA: Bullish | May 22, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 14, 2026 | 5 months ago |
| MACD: Sell Signal | May 12, 2026 | 5 months ago |
| RSI: Overbought | May 6, 2026 | 6 months ago |
| RSI: Overbought | May 4, 2026 | 6 months ago |
Key statistics
- Market cap
- 1.01B
- Enterprise value
- 933.60M
- Trailing P/E
- 0.00
- Forward P/E
- -5.17
- PEG ratio
- 0.00
- Price / sales
- 7.62
- Price / book
- 2.27
- EPS (TTM)
- -5.06
- Beta
- 1.79
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -219.61%
- Revenue (TTM)
- 132.42M
- Revenue growth
- -48.50%
- Free cash flow
- -72.40M
- Total cash
- 302.16M
- Total debt
- 404.11M
- Return on equity
- -59.94%
- Shares outstanding
- 55.38M
- Short % of float
- 13.36%
- 50-day average
- 8.08
- 200-day average
- 8.32
Analyst view
Consensus: none
- Target (low)
- 5.00
- Target (mean)
- 7.00
- Target (high)
- 9.00
- Strong buy0
- Buy0
- Hold1
- Sell1
- Strong sell1
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.58.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.58 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | -0.895 | -0.75 | +0.15 | +16.20% |
| May 7, 2026 | Mar 31, 2026 | -1.21 | -1.39 | -0.18 | -14.77% |
| Feb 26, 2026 | Dec 31, 2025 | -1.80 | -1.42 | +0.38 | +21.11% |
| Nov 6, 2025 | Sep 30, 2025 | -1.24 | -1.45 | -0.21 | -16.94% |
| Aug 7, 2025 | Jun 30, 2025 | -1.44 | -1.10 | +0.34 | +23.61% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 4, 2026 | BTIG | reit | Sell | Sell |
| Aug 7, 2026 | TD Cowen | down | Buy | Hold |
| Mar 12, 2026 | BTIG | main | Sell | Sell |
| Jan 8, 2026 | TD Cowen | main | Buy | Buy |
| Aug 25, 2025 | BTIG | main | Sell | Sell |
| Sep 20, 2024 | TD Cowen | main | Buy | Buy |
About Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ginkgo.bio
News
- Ginkgo Bioworks Holdings, Inc. (DNA) Suffers a Larger Drop Than the General Market: Key Insights
- Cathie Wood Is Buying Archer Aviation Stock. Here's What History Says About Following Ark Into a Stock Down 62%.
- TD Cowen Maintains Hold on Ginkgo Bioworks Holdings, Raises Price Target to $11
- Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
- What's Going on With Ginkgo Bioworks Stock on Friday?
- Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
- Ginkgo Bioworks To Provide Autonomous Lab Access To NSF X-Labs Researchers, Contributing Cloud Lab Time And Protein Testing Services To $1.5B Science Program; To Provide Cloud Lab Time And Remote Access For NSF X-Labs Teams; To Offer Protein Testing Services To NSF X-Labs Teams
- Ginkgo Bioworks To Integrate Araceli Biosciences' Endeavor High-Content Imaging Instrument Into Nebula, The Company's Autonomous Lab
- Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks Moving Higher On Tuesday
- Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday
Your note
Sign in to keep a note on DNA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CANTON BARTHOLOMEW | Beneficial Owner of more than 10% of a Class of Security | Sale | Apr 9, 2026 | 0 |
| COEN STEVEN P. | Chief Financial Officer | Sale | Aug 23, 2026 | 51,851 |
| DMYTRUK MARK E | Chief Financial Officer | Sale | May 20, 2025 | 46,226 |
| HANNAN KATHY HOPINKAH | Director | Conversion of Exercise of derivative security | Jun 10, 2025 | 15,003 |
| HENRY CHRISTIAN O | Director | Sale | Sep 14, 2026 | 19,310 |
| KELLY JASON R | Chief Executive Officer | Sale | Apr 8, 2026 | 316,483 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.73% | 4,282,903 | 64.16M | Jun 29, 2026 |
| Viking Global Investors, L.P. | 6.46% | 3,577,128 | 53.59M | Jun 29, 2026 |
| Erste Asset Management GmbH | 4.58% | 2,536,939 | 38.00M | Jun 29, 2026 |
| BAILLIE GIFFORD & CO | 4.32% | 2,391,649 | 35.83M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.77% | 2,087,293 | 31.27M | Jun 29, 2026 |
| Anchorage Capital Group, LLC | 3.15% | 1,746,363 | 26.16M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.69% | 1,489,851 | 22.32M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.23% | 1,232,832 | 18.47M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.99% | 550,071 | 8.24M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.94% | 523,147 | 7.84M | Jul 30, 2026 |
| PIMCO Equity Series-PIMCO RAE US Small Fund | 0.91% | 506,312 | 7.58M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 Value ETF | 0.80% | 441,778 | 6.62M | Aug 30, 2026 |